On September 9, 2021, Acorda Therapeutics, Inc. announced a corporate restructuring (the “Restructuring”) to reduce costs and more closely align operating expenses with expected revenue. The Company is reporting that Robert Morales, the Company’s Vice President, Finance and Controller and interim principal financial and accounting officer, has resigned from the Company with an effective date expected to be no later than the end of September 2021. Dr. Cohen has been appointed as the Company’s principal financial and accounting officer on an interim basis effective upon Mr. Morales’ departure.